Eli Lilly Bets $300M on Next-Gen Dual-Payload Cancer Therapy

ROCKVILLE, MD – April 14, 2026 – Pharmaceutical giant Eli Lilly and Company has announced a definitive agreement to acquire CrossBridge Bio, a preclinical biotechnology firm, in a deal worth up to $300 million. The acquisition gives Lilly control of a highly sought-after, next-generation antibody-drug conjugate (ADC) platform, underscoring a significant strategic investment in the future of precision oncology.

The deal, which includes an upfront payment and future milestone-based payments, marks a major validation for CrossBridge Bio, a Houston-based startup founded just three years ago. It also represents a significant win for early-stage investors like Linden Lake Labs, which participated in the company’s seed financing round in November 2024.

“This milestone reflects the power of investing early in pioneering science and exceptional teams,” said Abhishake Chhibber, Co-Founder of Linden Lake Labs, in a statement. “CrossBridge Bio is a strong example of that vision in action.”

A New Generation of "Smart Bombs" for Cancer

The acquisition centers on CrossBridge Bio's innovative dual-payload ADC technology, a platform that represents a major evolution in the field of targeted cancer therapy. ADCs, often described as biological “smart bombs,” are designed to deliver potent toxins directly to cancer cells while sparing healthy tissue. They consist of an antibody that seeks out a specific protein on the surface of tumor cells, a highly toxic payload, and a linker that connects the two.

CrossBridge Bio’s platform, which originated from research at The University of Texas Health Science Center at Houston, takes this concept a step further by attaching two distinct therapeutic payloads to a single antibody. This dual-payload approach is engineered to launch a multi-pronged attack on cancer cells, potentially enhancing efficacy, overcoming drug resistance, and producing more durable responses than conventional single-payload ADCs.

The company’s lead program, CBB-120, showcases this potential. It targets TROP2, a protein commonly overexpressed in a wide range of solid tumors, including breast, lung, pancreatic, and colorectal cancers. CBB-120 carries a combination of a Topoisomerase I inhibitor (TOP1i) and an ATR inhibitor (ATRi). This pairing is designed to create a synergistic effect: the TOP1i damages the cancer cell's DNA, and the ATRi prevents the cell from repairing that damage, leading to more effective cell death.

Preclinical studies have been highly promising. CBB-120 has demonstrated superior efficacy compared to other TROP2-targeting ADCs in drug-resistant models, achieving complete tumor regressions in some cases. The technology also features a highly stable linker, which prevents the premature release of its toxic payload in the bloodstream, suggesting a potentially improved safety profile with minimal off-target effects.

Lilly Fortifies its Oncology Arsenal

For Eli Lilly, the acquisition is a calculated move to bolster its oncology pipeline and assert its position in the fiercely competitive ADC market. The pharmaceutical industry has witnessed a frenzy of M&A activity centered on ADC technology, highlighted by Pfizer's landmark $43 billion acquisition of Seagen in 2023 and Johnson & Johnson’s purchase of Ambrx Biopharma earlier this year. These deals underscore a sector-wide consensus that ADCs are a cornerstone of modern cancer treatment.

This acquisition signals Lilly's aggressive return to the ADC space, building upon the strategic shift toward precision medicines that began with its $8 billion buyout of Loxo Oncology in 2019. While Lilly has been advancing its own internal ADC candidates, the CrossBridge Bio deal provides access to a cutting-edge, differentiated platform that could accelerate its development timelines and broaden its therapeutic capabilities. The addition of a dual-payload technology offers a distinct advantage in a field where overcoming tumor heterogeneity and treatment resistance is paramount.

Lilly's investment in CrossBridge Bio is not just about acquiring a single drug candidate but about securing a platform with the potential to generate a new class of cancer therapies. The planned Investigational New Drug (IND) submission for CBB-120 in 2026 will be a critical first step, but the underlying technology could be applied to other cancer targets within Lilly’s expanding oncology portfolio.

The Venture Capital Blueprint for Success

The deal is a textbook example of the high-risk, high-reward nature of life sciences venture capital. It shines a spotlight on the strategy of firms like Linden Lake Labs, which focus on identifying and nurturing groundbreaking science from its earliest stages. By providing not just capital but also strategic and operational support, these early-stage platforms help shepherd nascent technologies through critical value inflection points.

Linden Lake Labs, which participated in CrossBridge Bio’s seed round alongside investors such as the Texas Medical Center (TMC) Venture Fund and CE-Ventures, saw the potential in the dual-payload concept early on. Their investment supported the initial development and preclinical validation that ultimately attracted a major pharmaceutical partner.

“We are proud to have supported CrossBridge Bio from its early financing stages,” stated Thomas Haag, Co-Founder of Linden Lake Labs. “The team has executed with remarkable focus, advancing a highly innovative platform in a short period of time. We are excited to see this technology further developed within Lilly’s global infrastructure to potentially benefit patients across oncology.”

CrossBridge Bio's rapid trajectory from its founding in 2023 by Dr. Michael Torres, Dr. Kyoji Tsuchikama, and Dr. Zhiqiang An to a $300 million acquisition in 2026 is a testament to the strength of its science and the effectiveness of this venture-backed innovation model. The successful exit validates the approach of investing in foundational platforms and provides a powerful incentive for continued funding of early-stage biotech research.

With the backing of Lilly's extensive resources and clinical development expertise, the technology pioneered at a Houston university lab and accelerated by a nimble startup is now poised for the global stage. The journey of CBB-120 through clinical trials will be watched closely by the entire oncology community, as it carries the promise of a more powerful and precise weapon in the fight against cancer.